Clinical Trials
39
11 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
10
25.6%
Completed
21
53.9%
Not yet recruiting
1
2.6%
Recruiting
2
5.1%
Terminated
4
10.3%
Withdrawn
1
2.6%
No approval data available
- Shionogi has completed the succession of Japan Tobacco Inc.'s pharmaceutical business and acquisition of Akros Pharma Inc. shares through a simplified absorption-type company split. - The Japanese pharmaceutical company announced plans to merge with its wholly owned manufacturing subsidiary Shionogi Pharma Co., Ltd., effective April 1, 2027. - The merger aims to strengthen functional collaborations and build a robust production and supply system to adapt to environmental changes in the pharmaceutical supply chain. - Shionogi is accelerating globalization and business expansion primarily focused on in-house discovered infectious disease products under its SHIONOGI Transformation Strategy 2030 Revision.
- Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities. - The acquisition, negotiated since early 2024, will proceed through a tender offer beginning June 18 with a share price of ¥6,350 to acquire at least 11.89% of the minority stake. - This strategic move represents significant consolidation in the Japanese pharmaceutical sector and expands Shionogi's market presence amid increasing global competition.
